Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
暂无分享,去创建一个
M. Suarez‐Almazor | J. Wolchok | M. Atkins | I. Puzanov | M. Ernstoff | A. Naing | N. Leighl | J. Weber | J. Caterino | J. Brahmer | C. Lacchetti | P. Ginex | D. McDermott | I. Chau | John A Thompson | A. Spira | C. Reichner | B. Santomasso | S. Hallmeyer | J. H. Holter Chakrabarty | L. Nastoupil | B. Schneider | Tanyanika Phillips | Yinghong Wang | Kelly J. Brassil | Jennifer M. Gardner | J. Mammen | Laura D. Porter | C. Seigel | J. Thompson | Carole Seigel | T. Phillips | Jennifer L. Holter Chakrabarty
[1] M. Hara,et al. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease , 2018, Annals of Internal Medicine.
[2] M. Suarez‐Almazor,et al. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease , 2018, Annals of Internal Medicine.
[3] W. Barry,et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA oncology.
[4] A. Niemierko,et al. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy , 2017, JAMA oncology.
[5] Douglas B. Johnson,et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] J. Wolchok,et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] C. Lebbé,et al. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. , 2017, Annals of internal medicine.
[8] D. Sueta,et al. Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. , 2017 .
[9] Ami A. Shah,et al. Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature , 2017, Arthritis care & research.
[10] K. O'Byrne,et al. Pembrolizumab‐Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] M. Carlino,et al. Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] N. Staff,et al. Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies , 2017, JAMA neurology.
[13] Shreyaskumar R Patel,et al. Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. , 2017, The Canadian journal of cardiology.
[14] Shigeaki Suzuki,et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan , 2017, Neurology.
[15] R. Epstein,et al. Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Zhang,et al. Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis. , 2017, European journal of cancer.
[17] D. Schadendorf,et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Davies,et al. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events , 2017, ImmunoTargets and therapy.
[19] M. Suarez‐Almazor,et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series , 2017, Annals of the rheumatic diseases.
[20] E. Blackley,et al. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy , 2017, British Journal of Cancer.
[21] K. Kerr,et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] B. Carneiro,et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis , 2017, Cancer management and research.
[23] X. Mariette,et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment , 2017, Annals of the rheumatic diseases.
[24] N. Reinmuth,et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. , 2017, Cancer treatment reviews.
[25] A. Eggermont,et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] N. Kay,et al. How I treat autoimmune hemolytic anemia. , 2017, Blood.
[27] J. Abrams,et al. Toxicities associated with checkpoint inhibitor immunotherapy: The Karmanos Cancer Center experience. , 2017 .
[28] A. Abernethy,et al. Racial disparities in the use of programmed death-1 checkpoint inhibitors. , 2017 .
[29] Gerardo Cabanillas. Immune related adverse events and their treatment in melanoma patients receiving ipilimumab. , 2017 .
[30] C. Rudin,et al. Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. , 2017 .
[31] P. Coppo,et al. Thrombotic thrombocytopenic purpura. , 2017, Blood.
[32] J. Wargo,et al. Hallmarks of response to immune checkpoint blockade , 2017, British Journal of Cancer.
[33] P. Mazzone,et al. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death‐Ligand 1 Inhibitors in Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Trials , 2017, Chest.
[34] G. Lauwers,et al. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies , 2017, The American journal of surgical pathology.
[35] S. Zhang,et al. Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis , 2017, Molecular Cancer Therapeutics.
[36] A. Barac,et al. Cardiovascular Complications Associated With Novel Cancer Immunotherapies , 2017, Current Treatment Options in Cardiovascular Medicine.
[37] M. Suarez‐Almazor,et al. Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer , 2017, Arthritis & rheumatology.
[38] T. Münzel,et al. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma , 2017, Melanoma research.
[39] R. Gordon,et al. Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer , 2017, Asia-Pacific journal of oncology nursing.
[40] C. Callahan,et al. Cancer Immunotherapy: An evidence‐based overview and implications for practice , 2017, Clinical journal of oncology nursing.
[41] J. Lacour,et al. Pulmonary sarcoid‐like granulomatosis induced by nivolumab , 2017, The British journal of dermatology.
[42] S. Brant,et al. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis , 2017, World journal of gastroenterology.
[43] A. Vazquez. Hypophysitis: Nursing management of immune‐related adverse events , 2017, Clinical journal of oncology nursing.
[44] D. Schadendorf,et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] S. Cuzzubbo,et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. , 2017, European journal of cancer.
[46] C. Rudin,et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] T. Berg,et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. , 2017, Journal of hepatology.
[48] J. McQuade,et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy , 2017, Journal of Immunotherapy for Cancer.
[49] Douglas B. Johnson,et al. Cardiovascular Toxicities Associated with Cancer Immunotherapies , 2017, Current Cardiology Reports.
[50] A. Carneiro,et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis , 2017, Cancer Immunology, Immunotherapy.
[51] M. Garg,et al. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy , 2017, Front. Pharmacol..
[52] P. Armand,et al. Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant , 2017, Current Hematologic Malignancy Reports.
[53] R. Bresalier,et al. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors , 2017, Current Gastroenterology Reports.
[54] K. Jhaveri,et al. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review , 2017, American Journal of Nephrology.
[55] K. Jhaveri,et al. Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab. , 2017, The New England journal of medicine.
[56] L. Cooling,et al. Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation , 2017, Immunohematology.
[57] R. Sullivan,et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] V. Velcheti,et al. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases , 2016, Annals of the rheumatic diseases.
[59] Ami A. Shah,et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab , 2016, Annals of the rheumatic diseases.
[60] G. O’Kane,et al. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. , 2017, The oncologist.
[61] Ami A. Shah,et al. Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. , 2017, Immunotherapy.
[62] J. Larkin,et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] A. Giobbie-Hurder,et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.
[64] Paul R. Kunk,et al. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature , 2016, Journal of Immunotherapy for Cancer.
[65] J. Seidman,et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.
[66] G. Linette,et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. , 2016, The Lancet. Oncology.
[67] N. LeBoeuf,et al. Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management , 2016, Current opinion in urology.
[68] Carrie Lee,et al. Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma. , 2016, American journal of therapeutics.
[69] M. Murad,et al. Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.
[70] P. Sharma,et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial , 2016, The Lancet. Oncology.
[71] M. Postow,et al. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. , 2016, JAMA oncology.
[72] D. Schadendorf,et al. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. , 2016, The oncologist.
[73] Lajos Pusztai,et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] D. Leaf,et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. , 2016, Kidney international.
[75] M. Brown,et al. Vedolizumab: a novel treatment for ipilimumab-induced colitis , 2016, BMJ Case Reports.
[76] Hussein Tawbi,et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy , 2016, Journal of Immunotherapy for Cancer.
[77] C. Boils,et al. Use of the PD‐1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[78] E. Lipson,et al. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. , 2016, JAMA neurology.
[79] M. Suarez‐Almazor,et al. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports , 2016, PloS one.
[80] K. Akashi,et al. Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus , 2016, Medicine.
[81] J. Larkin,et al. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[82] A. V. van Bodegraven,et al. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[83] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[84] L. Vercellino,et al. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. , 2016, Chest.
[85] J. Wolchok,et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.
[86] G. Linette,et al. Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[87] P. Chanson,et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[88] D. Planchard,et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.
[89] S. Nair,et al. Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. , 2016, The New England journal of medicine.
[90] Xiaohong Xu,et al. The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials , 2016, OncoTargets and therapy.
[91] O. Abdel-Rahman,et al. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis , 2016, Therapeutic advances in respiratory disease.
[92] J. Taube,et al. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. , 2016, The New England journal of medicine.
[93] S. Ramalingam. Abstract IA24: Lung cancer: Disparities and implications for immunotherapy , 2016 .
[94] J. Larkin,et al. Management of toxicities of immune checkpoint inhibitors. , 2016, Cancer treatment reviews.
[95] C. Huttenhower,et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis , 2016, Nature Communications.
[96] R. Sullivan,et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.
[97] J. Soria,et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.
[98] Stefan R Bornstein,et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.
[99] C. Barrios,et al. The management of immune-related adverse events associated with immune checkpoint blockade , 2016 .
[100] Elie A Akl,et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.
[101] J. Soria,et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.
[102] K. Rubin. Understanding Immune Checkpoint Inhibitors for Effective Patient Care. , 2015, Clinical journal of oncology nursing.
[103] H. Elhalawani,et al. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. , 2015, Immunotherapy.
[104] G. Gibney,et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.
[105] E. Fliers,et al. Thyroid function in critically ill patients. , 2015, The lancet. Diabetes & endocrinology.
[106] J. Wolchok,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[107] E. Loftus,et al. Systematic review: colitis associated with anti‐CTLA‐4 therapy , 2015, Alimentary pharmacology & therapeutics.
[108] A. Amin,et al. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. , 2015, Translational lung cancer research.
[109] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[110] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[111] F. Hodi,et al. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab , 2015, Cancer Immunology Research.
[112] M. Atkins,et al. Toxicities of Immunotherapy for the Practitioner. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] C. Abrams,et al. How I treat refractory thrombotic thrombocytopenic purpura. , 2015, Blood.
[114] M. Socinski,et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. , 2015 .
[115] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[116] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[117] M. Postow. Managing immune checkpoint-blocking antibody side effects. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[118] P. Ascierto,et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.
[119] M. Bossard,et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.
[120] David C. Smith,et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[122] Seongseok Yun,et al. Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication , 2015, Case reports in oncological medicine.
[123] A. Zwinderman,et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] Gary H Lyman,et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] A. Giobbie-Hurder,et al. Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study , 2014, Clinical Cancer Research.
[126] R. Sullivan,et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. , 2014, The Journal of clinical endocrinology and metabolism.
[127] J. Wolchok,et al. Opportunistic infections in patients treated with immunotherapy for cancer , 2014, Journal of Immunotherapy for Cancer.
[128] N. Agarwal,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.
[129] David C. Smith,et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] J. Wolchok,et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. , 2014, Endocrine-related cancer.
[131] J. Rosenbaum,et al. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis , 2014, Biologics : targets & therapy.
[132] M. Lacouture,et al. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. , 2013, Journal of the American Academy of Dermatology.
[133] J. Weber,et al. Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma , 2013, Clinical Cancer Research.
[134] G. Gibney,et al. Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. , 2013 .
[135] D. Stover,et al. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. , 2013, Chest.
[136] L. Heinzerling,et al. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[137] A. Hauschild,et al. Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] J. Wolchok,et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[139] P. Beck‐Peccoz,et al. Diagnostic and therapeutic challenges of acquired thyrotropic deficiency. , 2012, Annales d'endocrinologie.
[140] J. Lozier. More on hemophilia A induced by ipilimumab. , 2012, New England Journal of Medicine.
[141] C. Mateus,et al. Hemophilia A induced by ipilimumab. , 2011, The New England journal of medicine.
[142] A. Hoos,et al. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] M. Crowther,et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.
[144] J. George,et al. How I treat patients with thrombotic thrombocytopenic purpura: 2010. , 2010, Blood.
[145] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[146] D. Schadendorf,et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.
[147] P. Collins,et al. Advances in the understanding of acquired haemophilia A: implications for clinical practice , 2010, British journal of haematology.
[148] Y. Maehara,et al. Severe interstitial pneumonitis associated with the administration of taxanes , 2010, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[149] Sana Syed,et al. Infliximab for the treatment of refractory scleritis , 2009, British Journal of Ophthalmology.
[150] I. Lowy,et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. , 2009, Blood.
[151] J. Weber. Ipilimumab: controversies in its development, utility and autoimmune adverse events , 2009, Cancer Immunology, Immunotherapy.
[152] S. O’Day,et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[153] S. Chasalow,et al. Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide , 2008 .
[154] H. Mead,et al. Racial and Ethnic Disparities in U.S. Health Care: A Chartbook , 2008 .
[155] S. Rosenberg,et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[156] S. Rosenberg,et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. , 2005, Journal of immunotherapy.
[157] M. Braun,et al. Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.
[158] J. George. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. , 2000, Blood.